|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM338770054 |
| 003 |
DE-627 |
| 005 |
20250303050506.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2022.108986
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1129.xml
|
| 035 |
|
|
|a (DE-627)NLM338770054
|
| 035 |
|
|
|a (NLM)35346865
|
| 035 |
|
|
|a (PII)S1521-6616(22)00067-5
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Qin, Jinlv
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Benefits of LAMA in patients with asthma-COPD overlap
|b A systematic review and meta-analysis
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.04.2022
|
| 500 |
|
|
|a Date Revised 20.05.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2022 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a PURPOSE: A systematic review and meta-analysis to determine the efficacy of long-acting muscarinic antagonist (LAMA) in patients with asthma-COPD overlap (ACO) was conducted
|
| 520 |
|
|
|a METHODS: A systematic search was made of PubMed, Embase, Cochrane Library, and clinicaltrials.gov, without language restrictions. Randomized controlled trials (RCTs) on treatment of ACO with LAMA, compared with placebo or blank, were reviewed
|
| 520 |
|
|
|a RESULTS: Six RCTs (enrolling 1151 participants) met the inclusion criteria. LAMA showed significant effects on forced expiratory volume in 1 s (FEV1) (WMD 98.31 mL, 95% CI 94.32 to 102.30 mL), forced vital capacity (FVC) (WMD 128.00 mL, 95% CI 121.89 to 134.12 mL), peak expiratory flow (PEF) (WMD 20.60 L/min, 95% CI 19.90 to 21.29 L/min), and rescue medicine use (WMD -0.67 puffs/day, 95% CI -1.11 to -0.23 puffs/day)
|
| 520 |
|
|
|a CONCLUSIONS: The addition of LAMA significantly improved lung function and rescue medicine use in patients with asthma-COPD overlap
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Meta-Analysis
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Systematic Review
|
| 650 |
|
4 |
|a Asthma-COPD overlap
|
| 650 |
|
4 |
|a Efficacy
|
| 650 |
|
4 |
|a LAMA
|
| 650 |
|
4 |
|a Meta-analysis
|
| 650 |
|
7 |
|a Adrenal Cortex Hormones
|2 NLM
|
| 650 |
|
7 |
|a Adrenergic beta-2 Receptor Agonists
|2 NLM
|
| 650 |
|
7 |
|a Muscarinic Antagonists
|2 NLM
|
| 700 |
1 |
|
|a Wang, Guizuo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Han, Dong
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 237(2022) vom: 25. Apr., Seite 108986
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:237
|g year:2022
|g day:25
|g month:04
|g pages:108986
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2022.108986
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 237
|j 2022
|b 25
|c 04
|h 108986
|